Clinical trial

Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

NCT06374043

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-05-11

PhasePHASE4

Study timeline

Study start (actual)2021-05-11Date precision: day

Registry last updated2024-04-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 2unresolved

Diabetes Mellitus Type 2 With Proteinuriaunresolved

Diabetes Mellitusunresolved

Diabetesunresolved

Diabetes Complicationsunresolved

Albuminuriaunresolved

Chronic Kidney Diseasesunresolved

Chronic Kidney Disease Due to Type 2 Diabetes Mellitusunresolved

CKDunresolved

Proteinuriaunresolved

Interventions

Dapagliflozin 10mg TabDRUG

Withings BPM ConnectDEVICE

Withings Body+DEVICE

Hem-Col Capillary Blood Collection DeviceDIAGNOSTIC_TEST

MEMS (Medication Electronic Monitoring System) CapDEVICE

Questionnaire: participants' perspectives toward remote data collectionBEHAVIORAL

Sponsors & collaborators

University Medical Center Groningenlead sponsor

AstraZenecacollaborator

Mapped research locations

GroningenNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06374043 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.